SUMMARY Increased concentration of the excitatory neurotransmitter aspartic acid in actively spiking human epileptic cerebral cortex was recently described.2 I In order to further characterise changes in the aspartergic system in epileptic brain, the behaviour of aspartic acid aminotransferase (AAT), a key enzyme involved in aspartic acid metabolism has now been examined. Electrocorticography performed during surgery was employed to identify cortical epileptic spike foci in 16 patients undergoing temporal lobectomy for intractable seizures. Patients with spontaneously spiking lateral temporal cortex (n = 8) were compared with a non-spiking control group (n = 8) of patients in whom the epileptic lesions were confined to the hippocampus sparing the temporal convexity. Mean activity of AAT in spiking cortex was significantly elevated by 16-18%, with aspartic acid concentration increased by 28%. Possible explanations for the enhanced AAT activity include increased proliferation of cortical AAT-containing astrocytes at the spiking focus and/or a generalised increase in neuronal or extraneuronal metabolism consequent to the ongoing epileptic discharge. It is suggested that the data provide additional support for a disturbance of central excitatory aspartic acid mechanisms in human epileptic brain.
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We have recently reported an increase in the concentration of two excitatory amino acid neurotransmitters, aspartic acid and glutamic acid, in actively spiking lateral temporal cortex excised for neurosurgical therapy of focal epilepsy.23 These changes may be especially relevant with respect to the pathophysiological processes in human focal cortical epilepsy in view of the experimental evidence that activation of central aspartic acid/glutamic acid systems may induce, in some brain areas, both seizure activity and concomitant neuronal damage. 4 As shown in the table, AAT activity measured in the direction of aspartic acid formation and degradation was significantly increased by 18 and 16% respectively, in spiking vs non-spiking cortex. In spiking cortex concentrations of aspartic and glutamic acid were significantly elevated by 34% and 28% respectively. An analysis of the individual values for AAT revealed little overlap between the spiking and non-spiking groups (especially in the direction of aspartic acid formation) with the majority of the spiking values falling outside the range of the non-spiking levels (see fig) . When the biochemical data from all 16 patients were subjected to regression analysis a significant positive correlation was observed between AAT activity measured in the direction of aspartic acid formation and in the direction of degradation (r = 083; p < 0 001). AAT activity was also significantly correlated with concentrations of aspartic acid (formation, r = 0 65; p < 0005; degradation, r = 0 48; p < 0-05) and glutamic acid (formation, r = 066; p < 0 005; degradation, r = 0-61; p < 0-01).
Specimens from-patients with superficial cortical spike foci tended to exhibit a greater degree of cortical astrogliosis and neuronal loss than those from the In this context, the possibility also has to be considered that the above-normal AAT levels in spiking cortex may be causally related to enhanced astroglial proliferation and activity. In this respect we observed in the 16 patients examined a slight, but statistically significant correlation between the activity of AAT in the direction of aspartic acid formation and extent of the histopathological changes (r, = 0 52, p < 0-02, Spearman Rank Order Correlation; p > 0-05 for histopathology vs. AAT in direction of aspartic acid degradation, aspartic acid or glutamic acid concentration). The enzyme AAT has been demonstrated to be present in especially high activities in astrocytes (1 1, cf. ref. 12) .
In our study all antiepileptic medication had been partially or completely withdrawn prior to operation. Most of the patients had received carbamazepine monotherapy and in all cases plasma levels had been in the lower therapeutic range for several weeks to permit EEG localisation. However, the possibility that these drugs even in low dosage may have influenced the amino acid and enzyme values cannot be excluded. None had received valproate which the acute administration of high doses in experimental animal studies is reported to result in a reduction in brain aspartate levels.'3 14 Aspartic acid concentration in cerebrospinal fluid has been reported to be higher in epileptic patients receiving antiepileptic polytherapy vs. patients without any medication. '5 With respect to functional considerations, much evidence now suggests the involvement of the excitatory neurotransmitter aspartic acid in seizure conditions as well as seizure-related-neuronal damage.
Sloviter and Dempster4 have provided evidence group.bmj.com on March 31, 2017 -Published by http://jnnp.bmj.com/ Downloaded from Aspartic acid aminotransferase activity in epilepsy that in rodents repeated intraventricular injection of aspartic acid produces both seizures and morphological changes in the hippocampus which were qualitatively similar to the changes observed in temporal lobe of epileptic patients. Similarly, Piredda and Gale' have recently demonstrated the ability of aspartic acid to induce bilateral motor seizures when microinjected into the deep prepiriform cortex of the rat. In the experimental literature studies of the behaviour of brain aspartic acid in a variety of animal models of convulsive seizures have produced no consistent pattern with aspartic acid levels reported as reported a strong correlation between the anticonvulsant potency of valproic acid analogues with their ability to reduce brain aspartic acid levels. These experimental data taken together with our present biochemical findings suggest the possibility of enhanced aspartic acid synthesis and neuronal release in actively spiking (but not with convulsions) epileptic human brain. This receives some additional support from the observations of increased aspartic acid levels in cerebrospinal fluid of epileptic patients.15 [35] [36] [37] Although the magnitude of the AAT 
